Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing treatments for bacterial infections, including multi-drug resistant infections, and rare diseases. Key pipeline candidates include Tebipenem HBr for complicated urinary tract infections, SPR720 for non-tuberculous mycobacterial infections, and SPR206 for MDR Gram-negative bacterial infections in hospitals.
Spero Therapeutics (SPRO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Spero Therapeutics's actual EPS was -$0.33, beating the estimate of -$0.39 per share, resulting in a 14.86% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
